Published: Thursday, June 12, 2025 · 5:45 PM | Updated: Thursday, June 12, 2025 · 5:45 PM
📊 203 views
🗝️ Key Points
- UCB (UCBJY, Financial) announces a $5 billion investment to expand biologics manufacturing capacity in the U.S.
- The project is expected to create 300 permanent high-skilled jobs and 500 construction jobs.
- workforce has grown by 73%, reaching 2,000 employees.UCB (UCBJY), a global biopharmaceutical company, has unveiled plans to construct a cutting-edge biologics manufacturing.
- Since 2017, UCB’s U.S. workforce has grown by 73%, reaching 2,000 employees.
UCB (UCBJY), a global biopharmaceutical company, has unveiled plans to construct a cutting-edge biologics manufacturing facility in the United States. This strategic move represents a significant expansion of UCB’s presence in the U.S., with an anticipated economic impact of approximately $5 billion. The initiative is also expected to generate 300 permanent high-skilled jobs and over 500 construction positions, demonstrating UCB’s commitment to bolstering the U.S. economy and healthcare sector.
Since 2017, UCB has increased its U.S. workforce by 73%, growing to 2,000 employees, alongside a substantial investment of $4.5 billion in acquisitions and capital improvements. This has bolstered its innovation capabilities and infrastructure, underlined by 15 FDA approvals or indication expansions, with eight approvals occurring in just the past two years.
The new facility aims to meet the demands of UCB’s growing U.S. Patient base and enhance the company’s global supply chain resilience. UCB is currently conducting a feasibility study to identify the optimal location for the facility, focusing on areas with strong talent pools and robust innovation Ecosystems.
MORE IN INSIDE INVESTMENT NEWS
We’re raising our Costco price target after a good but not great quarter. Here’s why
Published: Friday, March 6, 2026 · 12:27 AM
Broadcom stock rallies as CEO Tan makes strong case for why AI growth will last
Published: Thursday, March 5, 2026 · 4:04 PM
